covid
Buscar en
Revista Colombiana de Cancerología
Toda la web
Inicio Revista Colombiana de Cancerología Estudio de la estructura factorial de la escala de calidad de vida FACIT-P para ...
Información de la revista
Vol. 16. Núm. 3.
Páginas 162-169 (enero 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 16. Núm. 3.
Páginas 162-169 (enero 2011)
Acceso a texto completo
Estudio de la estructura factorial de la escala de calidad de vida FACIT-P para los pacientes con cáncer de próstata
A study of the FACIT-P quality of life factorial structure for prostate cancer patients
Visitas
3352
Mónica Ballesteros1, Ricardo Sánchez1,2,
Autor para correspondencia
rsanchezpe@unal.edu.co

Correspondencia: Ricardo Sánchez, Grupo Investigación Clínica, Instituto Nacional de Cancerología, Avenida 1a No. 9-85, Bogotá, D. C., Colombia. Tel.:éfono (571) 316 5000, ext. 15117.
, Bryan Merchán1, Rodolfo Varela3
1 Grupo Investigación Clínica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
2 Universidad Nacional de Colombia, Bogotá, D. C., Colombia
3 Grupo de Urología, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen
Objetivo

Realizar el análisis de la estructura de dominios de la escala FACIT-P (4.a versión), instrumento diseñado para medir el constructo de calidad de vida en pacientes con cáncer de próstata (CP).

Métodos

El método seleccionado para delimitar las variables latentes fue el de máxima verosimilitud. La estructura factorial escogida para buscar variables latentes partió de una rotación ortogonal tipo varimax.

Resultados

En los pacientes evaluados, más de la mitad procedían de Bogotá, la gran mayoría solo había cursado primaria, y de acuerdo con la escala Gleason, una cuarta parte presentaba un CP de grado intermedio o alto. Los dominios incluidos fueron: 1. aspectos que representan dolor y molestias; 2. elementos relacionados con autonomía y capacidad de desempeño; 3. aspectos de red social, familiar y satisfacción; 4. elementos relacionados con depresión y ansiedad; 5. síntomas específicos del cáncer de próstata.

Conclusiones

La estructura de dominios que muestra el instrumento en pacientes colombianos con CP mostró una organización de variables latentes plausible, y similares al constructo de la escala original.

Palabras clave:
Calidad de vida
neoplasias de la próstata
psicometría
cuestionarios
Abstract
Objective

To analyze the dominion structure of the FACIT-P scale (4th version), an instrument designed to measure the quality of life construct in prostate cancer (PC) patients.

Methods

The selected method sought to achieve greatest possible verisimilitude for discrimination of latent variables. The factorial structure chosen to single out latent variables was based upon varimax orthogonal rotation.

Results

More than half the number of patients evaluated came from Bogota; a large majority had only primary school education; on the Gleason scale, one fourth suffered from intermediate or high grade PC. Dominions included aspects related to: 1. Pain and discomfort; 2. Independence and performance capacity; 3. Social network, family life and contentment; 4. Depression and anxiety; 5. Specific symptoms related to prostate cancer.

Conclusions

The dominion structure produced by the instrument among Colombian PC patients revealed a plausible latent variable organization that resembled the original scale construct.

Key words:
Quality of life
prostatic neoplasms/drug therapy
prostatic neoplasms/psychology
psychometrics
questionnaires
El Texto completo está disponible en PDF
Referencias
[1.]
M.F. Leitzmann, S. Rohrmann.
Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates.
Clin Epidemiol, 4 (2012), pp. 1-11
[2.]
C. Maringe, P. Mangtani, B. Rachet, D.A. Leon, M.P. Coleman, I. Dos Santos Silva.
Cancer incidence in South Asian migrants to England, 1986–2004: Unraveling ethnic from socioeconomic differentials.
Int J Cancer, (2012),
[3.]
M. Outzen, K. Brasso, N. Martinussen, J. Christensen, A. Tjonneland, S. Friis, et al.
Prostate cancer in Denmark 1978–2009 - trends in incidence and mortality.
Acta Oncol, (2012),
[4.]
K. Shafique, R. Oliphant, D.S. Morrison.
The impact of socio-economic circumstances on overall and grade-specific prostate cancer incidence: a population-based study.
Br J Cancer, 107 (2012), pp. 575-582
[5.]
E. Scosyrev, G. Wu, S. Mohile, E.M. Messing.
Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation : Analysis of trends over time.
Cancer, (2012),
[6.]
Ferlay J, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0. Lyon, France [internet]. 2008 [citado: 17 de junio de 2011]. Disponible en: http://globocan.iarc.fr.
[7.]
M. Piñeros, J. Ferlay, R. Murillo.
Incidencia estimada y mortalidad por cáncer en Colombia: 1995–1999.
Imprenta Nacional, (2005),
[8.]
S.M. Hunt.
Cross-cultural comparability of quality of life measures.
Drug Inf J, 27 (1993), pp. 395-400
[9.]
M.E. O’Rourke.
Choose wisely: therapeutic decisions and quality of life in patients with prostate cancer.
Clin J Oncol Nurs, 11 (2007), pp. 401-408
[10.]
P. Esper, F. Mo, G. Chodak, M. Sinner, D. Cella, K.J. Pienta.
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.
[11.]
J.E. Batista-Miranda, C. Sevilla-Cecilia, R. Torrubia, M. Musquera, J. Huguet-Perez, X. Ponce de Leon, et al.
Quality of life in prostate cancer patients and controls: psychometric validation of the FACTP-4 in Spanish, and relation to urinary symptoms.
Arch Españ Urol, 56 (2003), pp. 447-454
[12.]
J.H. Hong, S.S. Jeon, H.M. Lee, Y.H. Choi, S. Kim, H.Y. Choi.
The Functional Assessment of Cancer Therapy-Prostate (FACTP) scales in men with prostate cancer: reliability and validity of the Korean version.
J Kor Med Sci, 21 (2006), pp. 295-299
[13.]
K. Webster, D. Cella, K. Yost.
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation.
Health Qual Life Out, 1 (2003), pp. 79
[14.]
F. Haseen, L.J. Murray, R.F. O’Neill, J.M. O'Sullivan, M.M. Cantwell.
A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy.
[15.]
C.J. Nelson, M.I. Weinberger, E. Balk, J. Holland, W. Breitbart, A.J. Roth.
The chronology of distress, anxiety, and depression in older prostate cancer patients.
Oncologist, 14 (2009), pp. 891-899
[16.]
M. Sia, G. Rodríguez, C. Menard, A. Bayley, R. Bristow, P. Chung, et al.
Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer.
Can Urol Assoc J, 4 (2010), pp. 105-111
[17.]
I. Syndikus, R.C. Morgan, M.R. Sydes, J.D. Graham, D.P. Dearnaley.
Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397).
Int J Rad Oncol, 77 (2010), pp. 773-783
[18.]
P. Warde, M. Mason, K. Ding, P. Kirkbride, M. Brundage, R. Cowan, et al.
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
Lancet, 378 (2011), pp. 2104-2111
[19.]
M.S. Litwin, R.D. Hays, A. Fink, P.A. Ganz, B. Leake, R.H. Brook.
The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.
Med Care, 36 (1998), pp. 1002-1012
[20.]
M.R. Stockler, D. Osoba, P. Goodwin, P. Corey, I.F. Tannock.
Responsiveness to change in health-related quality of life in a randomized clinical trial: a comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module. European Organization for Research and Treatment of Cancer.
J Clin Epidemiol, 51 (1998), pp. 137-145
[21.]
G. Van Andel, A. Bottomley, S.D. Fossa, F. Efficace, C. Coens, S. Guerif, et al.
An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer.
Eur J Cancer, 44 (2008), pp. 2418-2424
[22.]
B. Rosner.
Fundamentals of Biostatistics.
7th, Cengage Learning, (2011),
[23.]
M.A. Pett, N.R. Lackey, J.J. Sullivan.
Making sense of factor analysis. The use of factor analysis for instrument development in health care research.
Sage Pub, (2003),
[24.]
H.F. Kaiser.
The varimax criterion for analytic rotation in factor análisis.
Psychometrika, 23 (1958), pp. 187-200
[25.]
J.M. Fitzpatrick, M. Graefen, H.A. Payne, F. Scotte, M.S. Aapro.
A comment on the international society of geriatric oncology guidelines: evidence-based advice for the clinical setting.
[26.]
B. Hellerstedt, K.J. Pienta, B.G. Redman, P. Esper, R. Dunn, J. Fardig, et al.
Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
Cancer, 98 (2003), pp. 1603-1610
Copyright © 2012. Instituto Nacional de Cancerología
Descargar PDF
Opciones de artículo